CMN Weekly (25 October 2024) - Your Weekly CRISPR...
CMN Weekly
Oct. 25, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
AvenCell
Company Type: Therapeutics
Main focus: Development of autologous CAR-T cell therapies
Company stage: Pre-clinical
Diseases: Neurodegenerative disorders
Genome-editing tool: CRISPR-Cas
Funding stage: Series A
Location: Dresden, Germany
Website: https://avencell.com/
Pipeline: https://avencell.com/pipeline/
Partners:
AvenCell brings together switchable universal T-cell technology developed by the former Cellex subsidiary GEMoaB GmbH, with a license to Intellia Therapeutics proprietary CRISPR-Cas9-based allogeneic platform to create a pipeline of autologous and allogeneic universal reprogrammable T cell products, focused initially on hard-to-treat cancers.
